In Latvia, neuromuscular diseases, which affect about a thousand people, often have a lengthy diagnosis process, limited access to genetic testing, and a lack of available medications.
Neuromuscular diseases represent the largest group of rare diseases, impacting approximately one thousand individuals in Latvia. These diseases can affect nerve cells, nerves, muscles, or their connections, and they are often genetic or autoimmune in nature. Symptoms can appear at any age, and the progression of these diseases can vary significantly from person to person, making early diagnosis and treatment critical.
The path to diagnosis for neuromuscular diseases is frequently lengthy due to the necessity for doctors to recognize potential rare conditions and refer patients to specialists. Compounding this issue are the limited access to genetic testing and a shortage of funding for diagnostics. While some rare neuromuscular diseases currently have effective medications available, they are not always subsidized in Latvia, leading patients to face significant financial burdens for their treatment and care.
Patients with rare diseases also require ongoing rehabilitation, physiotherapy, and occupational therapy, but access to these supportive services is inconsistent. If treatment is not provided in a timely manner, the condition can progress, resulting in a loss of the individual's ability to work. Consequently, some patients are choosing to relocate to other countries where necessary medications and treatments are covered by national health systems, highlighting the urgent need for improvements in Latvia's healthcare provision for neuromuscular diseases.
